CBFβ-SMMHC-driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• The CBFB-MYH11 fusion gene is central to inv(16) acute myeloid leukemia (AML).
• The precise mechanism by which CBFB-MYH11 drives leukemogenesis, particularly its interaction with RUNX1, remains incompletely understood.

Purpose of the Study:

• To elucidate the role of the chimeric protein CBFβ-SMMHC in leukemogenesis.
• To investigate how CBFβ-SMMHC influences RUNX1 activity and DNA binding.
• To identify the key molecular events linking CBFβ-SMMHC to leukemia development.

Main Methods:

• In vitro binding assays to assess RUNX1-DNA interaction.
• Studies in myeloid progenitor cells from mice expressing CBFβ-SMMHC.
• Leukemia induction in mouse models with wild-type and mutated Runx1.
• Transcriptomic analysis to identify affected gene expression pathways.

Main Results:

• CBFβ-SMMHC enhances the binding affinity of RUNX1 to its target DNA.
• Leukemogenic potential of CBFβ-SMMHC correlates with its ability to boost RUNX1 DNA binding.
• Transcriptomic alterations in leukemic cells involve inflammatory response and CBFA2T3 target genes.
• A Runx1 mutation impairing DNA binding prevents CBFβ-SMMHC-induced leukemia.

Conclusions:

• Enhancing RUNX1 DNA binding affinity is a critical mechanism for CBFβ-SMMHC-mediated leukemogenesis.
• RUNX1-DNA interaction is a potential therapeutic target for inv(16) AML.
• The findings provide new insights into the molecular pathogenesis of this leukemia subtype.